[ad_1] Company receives the highest Water Security rating in two years into participation Recognized for exceptional leadership in environmental stewardship INCHEON, South Korea, Dec. 10, 2025 /PRNewswire/ — Samsung Biologics (KRX: 207940.KS), a leading contract development […]
[ad_1] Recorded Q3’25 consolidated revenue of KRW 1,660.2 billion Recorded Q3’25 consolidated operating profit of KRW 728.8 billion Delivered consistent performance through stable capacity ramp-up and strengthened global partnerships INCHEON, South Korea, Oct. 28, 2025 /PRNewswire/ — […]
[ad_1] INCHEON, South Korea, Oct. 21, 2024 /PRNewswire/ — Samsung Biologics (KRX: 207940.KS), a global contract development and manufacturing organization (CDMO), announced today a contract manufacturing deal with an Asia-based pharmaceutical company. The disclosed deal, […]
